News
Hepta Unveils First Multi-Omic Atlas of MASH, Linking Liver Pathway Biology to cfDNA Methylation in Blood
Hepta, a biotechnology company using transformer-based AI to decode the cell-free DNA (cfDNA) epigenome and detect organ-specific signals of chronic disease, today announced the creation of an unparalleled multi-omic atlas of metabolic dysfunction–associated steatohepatitis (MASH) in collaboration with Duke University. This work builds on Hepta’s expanded cfDNA studies with Mainz University and Akero Therapeutics’ Phase 3 clinical trial program, further strengthening the company’s partnerships across academic and clinical research.
Illumina and Grail Veterans Launch Hepta With First Liquid Biopsy-Native AI That Detects Liver Disease With Tissue-Level Biological Insights
Hepta, a biotechnology company using transformer-based AI to read the cell-free DNA (cfDNA) epigenome and detect organ-specific signals of chronic disease, today emerged from stealth with $6.7 million in seed funding led by Felicis Ventures and Illumina Ventures, with participation from SeaX Ventures, Alumni Ventures, and AME Cloud Ventures. The company also revealed clinical data showing its AI-powered epigenetics platform can identify patients with metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) with significant fibrosis with a diagnostic AUC of 0.86, cutting false positives threefold compared to standard blood tests.
Form Bio and Weill Cornell Medicine Announces Strategic Collaboration to Advance Gene Editing Therapy for Alzheimer's Disease
Form Bio partnered with Weill Cornell Medicine to apply AI-driven vector design and gene editing for developing therapies that lower Alzheimer’s disease risk in patients with high-risk genetic variants, marking the first phase of a multi-step clinical translation program.
Liverpool, CyanoCapture Team Up for Bionanotech Breakthrough
The University of Liverpool and CyanoCapture Ltd partnered to develop carboxysome-based targeted drug delivery systems by combining cyanobacteria engineering, peptide expression, and CRISPR-based molecular tools with scalable biomanufacturing to create protein nanocage platforms for biopharmaceutical applications.
Fork & Good Acquires Orbillion to Take Cultivated Red Meat Platform Global
Fork & Good acquired Orbillion Bio to combine their cultivated meat operations and accelerate the global commercialization of their red meat protein platform.
Samsung Life Science Fund Invests in Arbor Biotechnologies to Develop Next-Generation Genetic Medicines
Samsung Ventures invested in Arbor Biotechnologies to support the development of next-generation in vivo gene editing therapies for genetic diseases of the liver and central nervous system, reinforcing Samsung’s commitment to advancing biopharmaceutical technologies with meaningful clinical impact.
Valthos Secures $30 Million to Develop AI-Powered Biodefense Platform Against Biological Threats
Valthos raised $30 million in seed funding from OpenAI Startup Fund, Lux Capital, and Founders Fund to develop AI-driven biodefense systems that can identify biological sequences and design medical countermeasures in real time
ICHORtec and Johns Hopkins University Expand Collaboration to Enhance CRISPR Gene Editing Specificity Using Quantum FMB® Technology
ICHORtec expanded its collaboration with Johns Hopkins University to use its Quantum FMB® technology for improving the precision of CRISPR guide RNA design and evaluation, aiming to reduce off-target effects and enhance the accuracy of gene editing therapies.
Industry leaders use Knowledge Hub to explore 902+ Synthetic Biology news
Gain unparalleled insights, and drive your innovation forward.
Let’s shape tomorrow, today!